Kaufman Beth Zelnick net worth and biography

Kaufman Zelnick Biography and Net Worth

Insider of CorMedix

Beth Zelnick Kaufman was appointed as EVP, Chief Legal and Compliance Officer, and Corporate Secretary in December 2023. She leads the company’s legal and compliance activities. Prior to joining CorMedix, she most recently served as Chief Legal and Administrative Officer and Corporate Secretary of Akorn Pharmaceuticals, a specialty and generic pharmaceuticals company. Ms. Zelnick Kaufman also served as Chief Legal Officer of The Broad Institute of MIT & Harvard and in several roles at Amneal Pharmaceuticals, a publicly traded global generics, biosimilars, and branded pharmaceuticals company, including roles as Assistant General Counsel, Vice President, Legal Affairs, and Head of Government Affairs. Ms. Zelnick Kaufman holds a Juris Doctor degree from New York University Law School and a Bachelor of Arts degree from Amherst College.

What is Kaufman Beth Zelnick's net worth?: The estimated net worth of Kaufman Beth Zelnick is at least $1.14 million as of September 9th, 2025. Zelnick owns 180,418 shares of CorMedix stock worth more than $1,142,948 as of March 24th. This net worth evaluation does not reflect any other assets that Zelnick may own. Learn More about Kaufman Beth Zelnick's net worth.
How do I contact Kaufman Beth Zelnick?: The corporate mailing address for Zelnick and other CorMedix executives is 300 CONNELL DRIVE SUITE 4200, BERKELEY HEIGHTS NJ, 07922. CorMedix can also be reached via phone at (908) 517-9500 and via email at [email protected]. Learn More on Kaufman Beth Zelnick's contact information.
Has Kaufman Beth Zelnick been buying or selling shares of CorMedix?: Kaufman Beth Zelnick has not been actively trading shares of CorMedix during the last quarter. Most recently, Kaufman Beth Zelnick sold 50,000 shares of the business's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $13.41, for a transaction totalling $670,500.00. Following the completion of the sale, the insider now directly owns 180,418 shares of the company's stock, valued at $2,419,405.38. Learn More on Kaufman Beth Zelnick's trading history.
Who are CorMedix's active insiders?: CorMedix's insider roster includes Alan Dunton (Director), Elizabeth Hurlburt (EVP), Myron Kaplan (Director), Steven Lefkowitz (Director), Erin Mistry (EVP), Joseph Todisco (CEO), and Kaufman Zelnick (Insider). Learn More on CorMedix's active insiders.
Are insiders buying or selling shares of CorMedix?: During the last twelve months, CorMedix insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $275,500.00. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 253,997 shares worth more than $3,258,817.44. The most recent insider tranaction occured on December, 30th when Director Alan W Dunton sold 20,000 shares worth more than $260,000.00. Insiders at CorMedix own 3.1% of the company. Learn More about insider trades at CorMedix.
Information on this page was last updated on 12/30/2025.

Kaufman Beth Zelnick Insider Trading History at CorMedix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/9/2025	Sell	50,000	$13.41	$670,500.00	180,418

Kaufman Beth Zelnick Buying and Selling Activity at CorMedix

CorMedix Company Overview

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Today's Range

Now: $6.46

$6.31

$6.48

50 Day Range

MA: $7.12

$6.25

$8.17

2 Week Range

Now: $6.46

$5.60

$17.43

Volume

1,272,468 shs

Average Volume

2,583,997 shs

Market Capitalization

$510.66 million

P/E Ratio

3.23

Dividend Yield

N/A

Beta

1.31